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Abstract
ROBO1 is a strong candidate gene for age-related macular degeneration (AMD) based upon its location under a linkage peak
on chromosome 3p12, its expression pattern, and its purported function in a pathway that includes RORA, a gene previously
associated with risk for neovascular AMD. Previously, we observed that expression of ROBO1 and RORA is down-regulated
among wet AMD cases, as compared to their unaffected siblings. Thus, we hypothesized that contribution of association
signals in ROBO1, and interaction between these two genes may be important for both wet and dry AMD. We evaluated
association of 19 single nucleotide polymorphisms (SNPs) in ROBO1 with wet and dry stages of AMD in a sibling cohort and
a Greek case-control cohort containing 491 wet AMD cases, 174 dry AMD cases and 411 controls. Association signals and
interaction results were replicated in an independent prospective cohort (1070 controls, 164 wet AMD cases, 293 dry AMD
cases). The most significantly associated ROBO1 SNPs were rs1387665 under an additive model (meta P=0.028) for wet AMD
and rs9309833 under a recessive model (meta P=6610
24) for dry AMD. Further analyses revealed interaction between
ROBO1 rs9309833 and RORA rs8034864 for both wet and dry AMD (interaction P,0.05). These studies were further
supported by whole transcriptome expression profile studies from 66 human donor eyes and chromatin immunoprecip-
itation assays from mouse retinas. These findings suggest that distinct ROBO1 variants may influence the risk of wet and dry
AMD, and the effects of ROBO1 on AMD risk may be modulated by RORA variants.
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Introduction
Age-related macular degeneration (AMD) is a progressive
retinal disease that severely reduces the quality of life. Unfortu-
nately, medical treatments are limited particularly early in the
course of disease before vision loss occurs. It is the most common
cause of visual loss in the US with 10% prevalence in those 40 and
older having any AMD and affecting more than 20 million people
worldwide.[1] The disorder is more prevalent in whites than other
ethnic groups, with almost eight-fold greater incidence than in
African Americans for advanced AMD. The disease occurs equally
in men and women.[1] There are two advanced clinical subtypes
of AMD, non-exudative (geographic atrophy) and exudative
(neovascular or wet). Although these advanced subtypes may have
different pathophysiologic mechanisms, both can be preceded by
the development of drusen (yellow-gray material in Bruch’s
membrane) and retinal pigment epithelium (RPE) changes that
progress into areas of atrophy, or in the case of wet AMD, the
growth of new vessels from the choroid into the sub-RPE or sub-
retinal space. It is this wet AMD, the neovascular subtype, that is
responsible for loss of vision in the majority of cases. Therefore it is
important to identify appropriate therapeutic targets either for
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25775prevention or treatment of early stages of AMD to reduce
progression to these advanced stages.
Risk factors associated with AMD include family history,[2]
white race,[1] smoking,[3,4] and body mass index.[5] Prior studies
have shown an inverse relationship between omega-3 fatty acids
and the development of neovascular AMD.[6,7] There is also
evidence suggesting that hypertension and cataract surgery may
increase the predisposition to AMD.[8] The existence of a genetic
component to AMD was demonstrated initially by family studies
and twin studies with heritability estimates ranging from 45–
70%.[9] Two genetic variants, one in the complement factor H
(CFH) gene[10–12] and the other in the ARMS2/HTRA1 loci[13–
16] have been consistently reported as major attributable risks for
AMD. Association with a large number of additional loci, each
with small effect, has been reported.[17–19] The products of many
of these genes have a role in the complement system, cholesterol
metabolism and protein transport.
ROBO1 is a member of the immunoglobulin gene superfamily
and is involved in axon guidance and neuronal precursor cell
migration. ROBO1 has three isoforms that are produced by
alternative splicing. It is expressed in different tissues and
organs including the retinal ganglion cell layer of the eye in
mice and regulate the correct targeting of retinal ganglion cell
axons along the entire visual projection.[20,21] ROBO1
proteins are located on the cellular membrane and play a role
in cell-adhesion.[22] Prior studies implicated ROBO1 in ocular
neovascularization via SLIT-ROBO1 signaling[23] and
showed that inhibiting its expression in RPE cells resulted in
suppression of proliferative vitreoretinopathy in animals.[24–
26] Genetic association of ROBO1 polymorphisms and AMD
has not been reported thus far.
The chromosome 15q-linked RORA gene encodes the alpha
retinoic acid receptor-related orphan receptor. It is associated with
the development of the cerebellum and, together with RORB, with
the maturation of photoreceptors in the retina. RORA has been
implicated in the pathology of circadian rhythms, bone growth,
angiogenesis, development of cones, cellular metabolism and a
mediator in the immune and lipid metabolism pathways.[27]
Linkage, association and expression studies have implicated RORA
in AMD pathogenesis.[28]
Our previous expression study reported that RORA and ROBO1
are down-regulated at least two-fold among affected individuals
compared with their unaffected siblings.[28] In light of the
involvement of ROBO1 and RORA in eye development, specifically
the retina, and our previous expression results, we investigated the
association of AMD risk with ROBO1 and the interaction of these
two genes.
Results
Association of ROBO1 SNPs with Wet and Dry AMD
The mean ages at exam in the New England Sibling Cohort
(NESC) and an unrelated cohort from central Greece (GREEK)
were comparable, but older by about 10 years than the mean age
at diagnosis in the Nurses’ Health Study and Health Professionals
Follow-up Study (NHS-HPFS) (Table 1). Because significant
differences were seen between age and sex distribution among
the three cohorts, all analyses included both these variables as
covariates in order to control for their confounding effects.
Analysis of linkage disequilibrium (LD) among ROBO1 SNPs
revealed a minimum of three distinct haplotype blocks (Figure S1):
the first block encompassing the region between rs1387665 and
rs4264688, the second between rs6548621 to rs9826366, and the
third block including rs3923526, rs9309833, and rs7629503.
A total of 37 SNPs were identified in the discovery cohorts (for
listing of SNPs see Table S1). Of these 37 SNPs, we focused on 19
tag SNPs, that reside upstream of the isoform b and in intron 3 of
the isoform a in the human sequence (Table 2). We investigated
association for neovascular (wet) form of AMD and dry AMD
(Age Related Eye Disease Study [AREDS] category 2 and 3). In
the NESC, five of the 19 ROBO1 SNPs were associated with wet
AMD at a nominal significance level at P,0.05 (Table 2). None
of these SNPs were significantly associated with wet AMD in the
GREEK cohort (P.0.05). Meta-analysis of the two cohorts
revealed three SNPs from the middle LD block showed mild
association (most significant SNP: rs7637338 with P=0.021). The
minor allele A of rs7637338 showed increased risk with an odds
ratio (OR) of 1.39 (95% confidence interval [CI] =1.05–1.84).
Three 5’ SNPs were moderately significant with dry AMD in the
NESC, of which rs9309833 was the most significant (P=0.005)
(Table 3). Although these SNPs were not significant at P,0.05 in
the GREEK cohort, the direction of effect was the same for each
(Table 3) and the SNP rs9309833 remained significant in meta-
analysis (meta P=0.015). The two most significant SNPs for wet
AMD (rs7637338) and for dry AMD (rs9309833) are uncorrelat-
ed (Figure S1) in both cohorts (r
2,0.06), suggesting the possibility
that these two signals are tagging independent causal variants in
this gene.
Our findings were extended to testing different genetic models
with four SNPs covering each LD block and attempting to confirm
the results in the NHS-NPFS replication cohort (Table 4). We
confirmed association signals in the first block of ROBO1 for wet
AMD, with rs1387665 being the most significant under an
additive model in meta-analysis of the three datasets (meta
P=0.028; OR=1.18, CI=1.02–1.37). However, this SNP was
not associated with dry AMD (meta P.0.14). In contrast,
rs9309833 from the third block was more strongly associated with
dry AMD (meta P=6610
24; OR=2.54, CI=1.49–4.34) than
with wet AMD (meta P=0.047; OR=1.88, CI=0.99–3.56)
under a recessive model. The association signal with rs9309833 for
dry AMD remained significant even after adjusting for testing
multiple SNPs, models, and traits (threshold P=0.002 obtained
Table 1. Description of Datasets.
Study and Description AMD
Controls Wet AMD Dry AMD
NESC
Total, N 198 352 106
Average age at exam (SD) 75.40 (8.25) 73.80 (7.77) 76.65 (12.32)
Gender (% of female) 56.1% 59.4% 65.1%
Greek
Total, N 213 139 68
Average age at exam (years) 73.78 (7.25) 76.33 (7.49) 74.44 (7.99)
Gender (% of female) 53.1% 58.8% 54.7%
NHS/HPFS
Total, N 1070 164 293
Average age at exam (years) 60.21 (5.9) 61.07 (6.0) 59.53 (5.7)
Gender (% of female) 63.6% 54.3% 70.7%
Abbreviations: SD, standard deviation; NESC, New England Sibling Cohort;
Greek, central Greece cohort; NHS/HPFS, Nurses’ Health Study (NHS) and Health
Professionals Follow-up Study (HPFS).
doi:10.1371/journal.pone.0025775.t001
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2=0) between
rs1387665 and rs9309833 in all cohorts. These results suggest that
there may be two or more independent causal variants residing in
the different regions of the ROBO1, and the genetic models
governing the effect of these variants may differ for wet and dry
AMD.
Interaction between ROBO1 and RORA
Four ROBO1 tagging SNPs (rs1387665, rs4513416, rs7622444,
and rs9309833) in a region that likely harbors alternative splice
sites were selected for interaction analysis based on LD patterns in
the region (Figure S1). Among the previously reported significant
RORA SNPs for wet AMD (rs4335725 and rs8034864), haplotypes
containing rs8034864 had the most consistent evidence of
association in meta-analysis (Table 5). We therefore constructed
additive models including one of four significant ROBO1 SNPs, the
RORA SNP (rs8034864), and an interaction term for the ROBO1
and RORA SNPs. Other genetic models were not tested because of
small sample sizes for many of the SNP6SNP genotype cells.
Moderately significant interactions were found between RORA
rs8034864 and ROBO1 SNPs for both wet and dry AMD (Table 6).
The interaction of rs8034864 and rs4513416 from the ROBO1
gene remained significant (meta P for interaction =0.0042) after
correction for testing eight interaction models (threshold
P=0.006). There was also significant evidence of interaction
between ROBO1 SNP rs9309833 and RORA SNP rs8034864 in
affecting the risk of both wet (meta P for interaction =0.010) and
early/intermediate dry AMD (meta P for interaction =0.037).
The effect direction of these significant SNPs and the pattern of
their interactions for early/intermediate dry AMD were consistent
in all datasets (Table 6).
Analysis of the full logistic models (Fig. 1) revealed that
comparing with the dosage effect of the rs4513416 C allele for
wet AMD (Fig. 1A) that for early/intermediate dry AMD was
modulated by the dose of the rs8034864 T allele (Fig. 1B).
Interaction between ROBO1 SNP rs9309833 and RORA SNP
rs8034864 was significant for both wet (Fig. 1C) and early/
intermediate dry AMD (Fig. 1D) such that risk of AMD increased
according to dose of the rs8034864 G allele among rs9309833 AA
homozygotes, whereas AMD risk decreased according to dose of
the rs8034864 G allele among rs9309833 GG homozygotes.
Chromatin Immunoprecipitation (ChIP) Assays
The protein encoded by the RORA gene is known to bind to
response elements of several genes to enhance the expression of
those genes.We conductedan experiment to test whether the RORA
gene product (Rora) binds to regulatory sequence elements of the
ROBO1 gene to determine if Rora directly binds to and can regulate
Robo1 gene expression in vivo. A recent report suggested that the
Rora putative response element recognition sequence is RGGTCA
where R represents any purines.[27] We evaluated approximately
30 kilobases (kb) of Robo1 5’ untranslated regulatory region and
also intron 1 to identify a putative Rora binding site in mouse. A
potential binding site consisting of ATATG[GGTCA] 24,200 bp
from the Robo1 start codon was identified (Fig. 2A). This binding
site (at base pair position 79,091,190in human) corresponds to a site
338,621 base pairs downstream of the first significantly associated
ROBO1 promoter SNP, rs1387665.
Table 2. Association results of ROBO1 SNPs for wet AMD in the NESC and GREEK cohorts, and in meta-analysis using an additive
model.
SNP Alleles RA (RAF) NESC GREEK Meta-Analysis
OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs1387665 G/A A (0.52) 1.20 (0.94–1.53) 0.135 1.18 (0.84–1.66) 0.326 1.20 (0.98–1.46) 0.074
rs13076006 C/A A (0.38) 0.76 (0.59–0.98) 0.036 1.03 (0.72–1.48) 0.867 0.84 (0.68–1.04) 0.105
rs4513416 T/C T (0.38) 0.80 (0.63–1.03) 0.085 0.97 (0.69–1.38) 0.875 0.86 (0.70–1.05) 0.135
rs9810404 C/T C (0.38) 0.79 (0.62–1.02) 0.068 1.02 (0.71–1.45) 0.934 0.86 (0.70–1.06) 0.150
rs7640053 C/A C (0.38) 0.80 (0.62–1.02) 0.077 0.95 (0.67–1.35) 0.789 0.85 (0.69–1.04) 0.111
rs7615149 C/A C (0.33) 0.79 (0.62–1.01) 0.060 1.04 (0.72–1.49) 0.850 0.86 (0.70–1.05) 0.148
rs7622888 C/T C (0.32) 0.97 (0.74–1.27) 0.831 1.14 (0.77–1.71) 0.510 1.02 (0.82–1.28) 0.852
rs4264688 T/C T (0.32) 0.99 (0.77–1.28) 0.949 1.15 (0.76–1.73) 0.518 1.03 (0.83–1.28) 0.778
rs6548621 A/G A (0.42) 0.77 (0.61–0.97) 0.028 0.94 (0.66–1.33) 0.715 0.82 (0.67–0.99) 0.043
rs7622444 G/A G (0.22) 1.44 (1.08–1.92) 0.013 1.05 (0.67–1.65) 0.819 1.32 (1.03–1.68) 0.026
rs9832405 A/G A (0.41) 0.94 (0.75–1.19) 0.632 0.90 (0.61–1.34) 0.616 0.93 (0.76–1.14) 0.504
rs7637338 A/G A (0.14) 1.31 (0.93–1.85) 0.125 1.56 (0.97–2.51) 0.068 1.39 (1.05–1.84) 0.021
rs6548625 C/T C (0.34) 0.77 (0.60–0.99) 0.040 1.05 (0.74–1.50) 0.785 0.85 (0.70–1.05) 0.125
rs7623809 A/G A (0.36) 0.78 (0.60–1.00) 0.054 1.04 (0.72–1.49) 0.840 0.86 (0.69–1.06) 0.146
rs4279056 G/A G (0.38) 0.79 (0.62–1.02) 0.067 0.98 (0.69–1.39) 0.916 0.85 (0.69–1.04) 0.120
rs9826366 G/A G (0.38) 0.81 (0.63–1.04) 0.099 0.96 (0.68–1.37) 0.843 0.86 (0.70–1.05) 0.144
rs3923526 T/A T (0.16) 1.24 (0.91–1.70) 0.171 1.08 (0.70–1.66) 0.729 1.18 (0.92–1.53) 0.190
rs9309833 G/A G (0.16) 1.43 (1.03–1.99) 0.035 0.95 (0.60–1.52) 0.838 1.25 (0.95–1.64) 0.108
rs7629503 T/G T (0.27) 1.18 (0.90–1.53) 0.226 1.06 (0.73–1.53) 0.750 1.14 (0.92–1.41) 0.241
Alleles were provided from the plus (+) strand using the NCBI B36 assembly of dbSNP b126.
Abbreviations: SNP, Single Nucleotide Polymorphism; RA: reference allele used in association tests; RAF: reference allele frequency; OR: odds ratio; 95% CI: 95%
confidence interval; P: P value.
doi:10.1371/journal.pone.0025775.t002
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normal (C57BL6/J) mouse retinas. Rora binding to Robo1
regulatory region was determined by quantitative real time
PCR (Fig. 2B). The green opsin (Opn1mw) locus control
region was previously reported as a Rora binding site and
therefore served as a positive control.[29] We confirmed the
Table 3. Association results of ROBO1 SNPs for dry AMD in the NESC and GREEK cohorts, and in meta-analysis using an additive
model.
SNP Alleles RA (RAF) NESC GREEK Meta-Analysis
OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs1387665 G/A A (0.49) 0.94 (0.66–1.36) 0.749 1.07 (0.71–1.61) 0.747 1.00 (0.76–1.31) 0.981
rs13076006 C/A C (0.41) 1.15 (0.79–1.68) 0.456 0.86 (0.56–1.34) 0.511 1.02 (0.77–1.36) 0.890
rs4513416 T/C T (0.41) 1.17 (0.81–1.70) 0.400 0.96 (0.62–1.47) 0.838 1.08 (0.81–1.43) 0.614
rs9810404 C/T C (0.41) 1.17 (0.81–1.70) 0.392 0.93 (0.60–1.43) 0.728 1.06 (0.80–1.41) 0.670
rs7640053 C/A C (0.40) 1.16 (0.80–1.68) 0.447 0.80 (0.52–1.24) 0.322 0.99 (0.75–1.32) 0.949
rs7615149 C/A C (0.35) 1.11 (0.77–1.60) 0.589 0.74 (0.47–1.18) 0.208 0.95 (0.71–1.26) 0.717
rs7622888 C/T C (0.32) 1.06 (0.70–1.62) 0.780 1.27 (0.79–2.04) 0.322 1.15 (0.84–1.57) 0.386
rs4264688 T/C T (0.31) 0.99 (0.64–1.51) 0.949 1.27 (0.79–2.04) 0.331 1.10 (0.80–1.52) 0.547
rs6548621 A/G A (0.44) 0.92 (0.66–1.29) 0.633 1.00 (0.66–1.52) 0.992 0.95 (0.73–1.24) 0.716
rs7622444 G/A G (0.20) 1.01 (0.63–1.62) 0.967 0.82 (0.46–1.46) 0.508 0.93 (0.65–1.34) 0.698
rs9832405 A/G A (0.41) 0.90 (0.61–1.33) 0.591 1.49 (0.95–2.33) 0.085 1.11 (0.83–1.50) 0.470
rs7637338 A/G A (0.12) 0.79 (0.44–1.44) 0.447 1.00 (0.50–1.98) 0.995 0.88 (0.56–1.37) 0.563
rs6548625 C/T C (0.36) 1.00 (0.70–1.44) 0.990 0.75 (0.48–1.18) 0.212 0.89 (0.68–1.19) 0.440
rs7623809 A/G A (0.38) 0.99 (0.68–1.45) 0.966 0.70 (0.44–1.11) 0.134 0.86 (0.64–1.16) 0.323
rs4279056 G/A G (0.40) 1.03 (0.72–1.47) 0.878 0.72 (0.46–1.12) 0.142 0.89 (0.67–1.18) 0.421
rs9826366 G/A G (0.40) 1.04 (0.72–1.49) 0.851 0.72 (0.46–1.12) 0.142 0.89 (0.68–1.18) 0.435
rs3923526 T/A T (0.17) 1.73 (1.08–2.76) 0.023 1.22 (0.73–2.06) 0.447 1.48 (1.04–2.09) 0.028
rs9309833 G/A G (0.17) 2.01 (1.24–3.27) 0.005 1.15 (0.69–1.94) 0.588 1.56 (1.09–2.22) 0.015
rs7629503 T/G T (0.28) 1.75 (1.13–2.69) 0.011 1.05 (0.67–1.63) 0.831 1.36 (1.00–1.85) 0.050
Alleles were provided from the plus (+) strand using the NCBI B36 assembly of dbSNP b126.
Abbreviations: SNP, Single Nucleotide Polymorphism; RA: reference allele used in association tests; RAF: reference allele frequency; OR: odds ratio; 95% CI: 95%
confidence interval; P: P value.
doi:10.1371/journal.pone.0025775.t003
Table 4. Association results of ROBO1 SNPs for wet AMD or dry AMD in meta-analysis under the three different genetic models
(additive, dominant, and recessive) from the combined dataset including the NESC, the GREEK, and the NHS-HPFS cohort.
SNP Model RA Wet AMD Dry AMD
OR (95% CI) P OR (95% CI) P
rs1387665 Add A 1.18 (1.02–1.37) 0.0281 1.10 (0.95–1.28) 0.2179
Dom 1.23 (0.96–1.58) 0.1027 1.21 (0.94–1.55) 0.1462
Rec 1.28 (1.00–1.64) 0.0490 1.08 (0.84–1.38) 0.5413
rs4513416 Add T 0.88 (0.75–1.02) 0.0979 0.93 (0.80–1.09) 0.3680
Dom 0.81 (0.64–1.02) 0.0687 0.91 (0.73–1.14) 0.4212
Rec 0.90 (0.67–1.19) 0.4486 0.91 (0.68–1.22) 0.5151
rs7622444 Add G 1.11 (0.91–1.36) 0.2870 0.90 (0.73–1.11) 0.3093
Dom 1.05 (0.83–1.32) 0.6948 0.82 (0.64–1.04) 0.0969
Rec 1.74 (0.95–3.19) 0.0703 1.66 (0.91–3.02) 0.0993
rs9309833 Add G 1.18 (0.96–1.44) 0.1150 1.33 (1.09–1.61) 0.0041
Dom 1.13 (0.90–1.43) 0.3000 1.26 (1.01–1.59) 0.0451
Rec 2.00 (1.01–3.96) 0.0465 2.54 (1.49–4.34) 6610
24
Alleles were provided from the plus (+) strand using the NCBI B36 assembly of dbSNP b126.
Abbreviations: SNP, Single Nucleotide Polymorphism; RA: reference allele used in association tests; OR: odds ratio; 95% CI: 95% confidence interval; P: P value.
doi:10.1371/journal.pone.0025775.t004
Interaction of ROBO1 and RORA in AMD
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25775binding affinity between Rora and Robo1 regulatory region
with similar strength compared with that with the positive
control (Fig. 2B). The absence of amplification from IgG
precipitated samples demonstrated the specificity of the Rora
antibody and validated the binding of Rora to the Robo1
response element sequence.
Gene Expression Profiling in Human Donor Eyes
Expression of both ROBO1 and RORA was detected in the RPE-
choroid and the retina. Of the genes examined in a whole
transcriptome analysis of ocular tissues derived from 66 human
donors, no significant association as a function of age was
observed. We did not observe statistically significant differences in
Table 5. Significant haplotypes in RORA for wet AMD in the NESC, GREEK, NHS-HPFS cohorts, and in meta-analysis using an
additive model.
NESC GREEK NHS-HPFS Meta-Analysis
Haplotype OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs8034864-rs730754 0.96 (0.56–1.67) 0.8959 1.36 (0.86–2.14) 0.1920 1.34 (1.01–1.79) 0.0417 1.28 (1.02–1.59) 0.0307
(T-G)
rs8034864- rs12900948 0.65 (0.37–1.13) 0.1277 1.56 (0.95–2.56) 0.0819 1.52 (1.14–2.06) 0.0082 1.31 (1.03–1.66) 0.0260
(T-C)
Abbreviations: OR: odds ratio; 95% CI: 95% confidence interval; P: P value.
doi:10.1371/journal.pone.0025775.t005
Table 6. Summary of interaction analysis of ROBO1 SNPs (rs4513416, rs7640053, rs7622444 and rs9309833) and a RORA SNP
(rs8034864) for wet and dry AMD in the three cohorts, NESC, GREEK, NHS-HPFS, and in meta-analysis.
ROBO16RORA (Allele) NESC GREEK NHS-HPFS Meta-Analysis
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Wet AMD:
rs1387665 (A) 1.18 (0.87–1.59) 0.2877 1.21 (0.74–1.97) 0.4556 1.20 (0.89–1.62) 0.2307 1.12 (0.92–1.37) 0.2414
rs8034864 (T) 0.96 (0.54–1.70) 0.8938 1.61 (0.71–3.65) 0.2528 1.20 (0.74–1.95) 0.4660 0.99 (0.71–1.39) 0.9641
INT 1.13 (0.72–1.75) 0.6001 0.54 (0.28–1.05) 0.0697 0.93 (0.63–1.39) 0.7368 1.12 (0.86–1.47) 0.4088
rs4513416 (T) 0.86 (0.63–1.18) 0.3516 1.57 (0.94–2.64) 0.0846 0.90 (0.67–1.21) 0.4682 0.96 (0.79–1.17) 0.6807
rs8034864 (T) 1.31 (0.83–2.08) 0.2514 2.13 (1.05–4.32) 0.0368 1.04 (0.67–1.61) 0.8604 1.28 (0.96–1.72) 0.0912
INT 0.82 (0.51–1.32) 0.4162 0.45 (0.23–0.89) 0.0212 1.05 (0.71–1.55) 0.8126 0.84 (0.64–1.11) 0.2129
rs7622444 (G) 1.58 (1.09–2.27) 0.0146 1.36 (0.70–2.67) 0.3684 0.70 (0.45–1.09) 0.1133 1.06 (0.82–1.37) 0.6541
rs8034864 (T) 1.20 (0.82–1.74) 0.3449 1.02 (0.59–1.75) 0.9492 0.92 (0.64–1.32) 0.6580 1.03 (0.82–1.31) 0.7836
INT 0.77 (0.47–1.26) 0.3062 0.56 (0.23–1.34) 0.1909 1.35 (0.74–2.46) 0.3222 1.07 (0.75–1.51) 0.7137
rs9309833 (G) 2.21 (1.39–3.49) 7.2E–04 0.71 (0.30–1.69) 0.4372 1.16 (0.79–1.68) 0.4537 1.49 (1.13–1.97) 0.0046
rs8034864 (T) 1.35 (0.97–1.87) 0.0788 0.73 (0.42–1.28) 0.2740 1.19 (0.84–1.70) 0.3333 1.29 (1.03–1.60) 0.0265
INT 0.48 (0.28–0.79) 0.0044 1.61 (0.58–4.48) 0.3615 0.87 (0.52–1.45) 0.5893 0.64 (0.45–0.90) 0.0102
Dry AMD:
rs1387665 (A) 1.20 (0.78–1.86) 0.4047 0.66 (0.39–1.14) 0.1369 1.21 (0.96–1.51) 0.1023 1.24 (1.03–1.49) 0.0253
rs8034864 (T) 1.50 (0.79–2.88) 0.2166 0.64 (0.30–1.39) 0.2598 1.05 (0.71–1.55) 0.7968 1.21 (0.89–1.64) 0.2177
INT 0.60 (0.35–1.04) 0.0672 2.09 (1.03–4.25) 0.0404 0.89 (0.65–1.22) 0.4732 0.75 (0.58–0.97) 0.0291
rs4513416 (T) 0.84 (0.53–1.33) 0.4548 0.63 (0.35–1.13) 0.1233 0.81 (0.64–1.02) 0.0682 0.79 (0.65–0.96) 0.0180
rs8034864 (T) 0.57 (0.29–1.13) 0.1105 0.36 (0.15–0.86) 0.0217 0.79 (0.55–1.12) 0.1859 0.68 (0.51–0.91) 0.0101
INT 1.85 (1.08–3.19) 0.0260 2.30 (1.13–4.67) 0.0212 1.22 (0.89–1.67) 0.2198 1.45 (1.12–1.87) 0.0042
rs7622444 (G) 1.24 (0.72–2.15) 0.4339 1.68 (0.80–3.52) 0.1722 0.89 (0.65–1.21) 0.4537 0.91 (0.71–1.17) 0.4733
rs8034864 (T) 1.17 (0.72–1.89) 0.5290 1.61 (0.84–3.10) 0.1507 0.95 (0.72–1.25) 0.6964 0.94 (0.75–1.18) 0.6037
INT 0.59 (0.29–1.18) 0.1339 0.50 (0.19–1.33) 0.1657 0.97 (0.61–1.54) 0.8958 0.93 (0.65–1.34) 0.7140
rs9309833 (G) 3.67 (1.99–6.78) 3610–
5 1.11 (0.47–2.61) 0.8165 1.38 (1.04–1.82) 0.0248 1.55 (1.22–1.98) 4610
24
rs8034864 (T) 1.37 (0.83–2.26) 0.2112 1.57 (0.83–2.98) 0.1681 1.06 (0.80–1.41) 0.6940 1.05 (0.83–1.32) 0.6885
INT 0.36 (0.18–0.73) 0.0043 0.62 (0.23–1.69) 0.3501 0.77 (0.51–1.15) 0.2011 0.70 (0.50–0.98) 0.0367
Alleles were provided from the plus (+) strand using the NCBI B36 assembly of dbSNP b126. Bold cells represent nominally significant association with P,0.05.
Abbreviations: OR: odds ratio; 95% CI: 95% confidence interval; P: P value; INT: interaction term.
doi:10.1371/journal.pone.0025775.t006
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significantly different between the macula and extramacula in both
normal and AMD RPE-choroid (Fig. 3). This complements our
previous finding in immortalized cell lines, which showed ROBO1
had decreased expression by at least two fold in index patients with
neovascular AMD compared to their unaffected siblings.[28]
Discussion
We demonstrated significant association with ROBO1 SNPs
showing increased risk of wet and early/intermediate dry AMD in
a combined cohort of sibling pairs, cases and controls from Central
Greece, as well as a prospective case control study from the NHS/
HPFS. Moreover, we discovered variants from different LD blocks
that could explain the separate association signals for wet and early/
intermediate dry AMD. This suggests that different regions of this
gene may be responsible for risk of the different subtypes of AMD or
possibly indicate who may progress to wet or neovascular AMD,
which would have implications for therapeutic targets. Previous
genetic association studies reported that ROBO1 polymorphisms are
associated with other diseases of complex etiology. For example,
variation in ROBO1is associated with language ability[30] and shared
genetic factors between asthma and obesity in children.[31] A prior
study shows that ROBO1 is also associated with autism, showing that
mRNA expression is significantly down-regulated in those with
autism.[32] Furthermore, a role for Robo1 expression in retinal
angiogenesis has been demonstrated in a rabbit model of proliferative
retinopathy as well as in vitro studies of epiretinal and subretinal
membranes from patients with proliferative retinopathies.[25]
In addition to establishing association of ROBO1 with AMD, we
were able to document a statistically significant interaction
between ROBO1 and another AMD-associated gene, RORA.
RORA, a gene that is known to be involved in wet AMD based
on retrospective[28] and prospective[33] studies, regulates expres-
sion of genes in the mammalian clock mechanism[34] and in lipid
metabolism by changing levels of total plasma cholesterol,
triglycerides, and apolipoprotein.[35] DNA response elements of
RORA comprise a 5’ AT-rich sequence and along with
coactivators, change constitutive activation of target gene
transcription.[34] Interestingly, analogous to ROBO1, the protein
product of the RORA gene is also significantly reduced in the
autistic brain.[36] Statistical association and interaction with
ROBO1 and RORA genes were validated by a bioinformatic search
for response elements residing on ROBO1 sequences followed by
experimental confirmation using chromatin immunoprecipitation
assays and qRT-PCR in normal mouse maculae. Using the known
Rora response elements as a positive control, we established
similar quantity of precipitation with the regulatory region of the
ROBO1 gene as a potential Rora binding site. This gave further
evidence underlying a biological interaction between a Rora
product and the regulatory element of the ROBO1 gene. We are
currently extending the findings in mouse using chromatin
immunoprecipitation assays to direct sequencing in human donor
eyes and immortalized patient cell lines.
Our previous observation of down-regulation for ROBO1 in
immortalized cell lines[28] was validated in human donor RPE-
choroid and retina in the current study. Similar to the reduced
expression of this gene in autism, expression levels for ROBO1 in
Figure 1. Estimated probabilities for different categories of genotypes between ROBO1 SNPs and a RORA SNP in meta-analysis. X-
axis is the categories of genotypes for rs8034864 from the RORA gene, and Y-axis is the estimated probabilities of different genotypic groups for
rs4513416 (A and B) and rs9309833 (B and C) from the ROBO1 gene after adjusting for covariates. Graphs for wet AMD are shown in A and C, and for
dry AMD in B and D.
doi:10.1371/journal.pone.0025775.g001
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maculas and peripheral retinas were significantly reduced. This
also lends support for the hypothesis that AMD is a systemic
disease with a localized manifestation, as significant differences in
expression of ROBO1 on a systemic level, in cell lines,[28] was
confirmed on the DNA level although no differences in expression
of ROBO1 were seen between AMD eyes and non-AMD eyes. Our
findings along previous reports suggest that pathogenesis of
ROBO1 and RORA in complex diseases is potentially shared by
down-regulation of expression in response to neurodegeneration
and these findings could have significant implications for
therapeutic interventions and drug delivery.
Our statistical findings along with molecular verification have
improved our understanding on the potential synergetic effect of
ROBO1 and RORA in the early/intermediate AMD stages as well
as the severe advanced neovascular form of AMD. In addition to
the discovery of multiple variants in ROBO1 that may differentiate
wet and early/intermediate dry AMD, SNPs in ROBO1 were
found to interact with RORA in the early/intermediate dry form of
AMD in meta-analysis that were not found to significantly interact
in the neovascular AMD subtype as shown in Table 6.
The study design is unique from others such that we separated
two subtypes of AMD from all AMD or advanced AMD, to
investigate multiple variants that may be involved in the early/
intermediate or advanced/severe neovascular AMD subtype. This
approach is supported by an illustration of a review[37] that three
different components of AMD, drusen formation, neovasculariza-
tion, and RPE atrophy, have seen in many different complex
diseases, implying that there may be independent underlying
mechanisms to develop each of these components. A previous
study also demonstrated that drusen formation may have both
unique and shared underlying genetic mechanisms with interme-
diate or advanced AMD development.[38] Specifically, this study
showed that drusen formation as an intermediate stage of
advanced AMD types identified previously known linkage signals
for advanced AMD as well as novel peaks. One of the unique
Figure 2. RORA binding upstream to regulatory region of ROBO1.A .Schematic of ROBO1 gene and approximate location of RORA RE binding
site. B. qRT-PCR of ChIP samples using normal, adult, mouse retina identifies Robo1 as a target of Rora. Opn1mw was previously reported as a target
of RORA and is therefore a positive control. Neither Robo1 nor Opn1mw amplified out of the IgG ChIP (negative control).
doi:10.1371/journal.pone.0025775.g002
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accounted for the genotype of APOE gene. These further support
our results on differential association signals for wet and early/
intermediate dry AMD. Our hypothesis-driven, genomic conver-
gent approach based on prior biological plausibility provided
collective evidence from statistical tests and molecular experiments
demonstrating potentially yet another pathway underlying AMD
pathogenesis. Thus, our results, together with statistical findings
and molecular verification, warrant further investigation for both
diagnostics and therapeutics implications by taking both genes into
consideration, as they appear to work together.
Methods
Ethics Statement
This study was reviewed and approved by the Institutional
Review Boards (IRBs) at Massachusetts Eye and Ear Infirmary,
the University of Utah, and Boston University and conforms to the
tenets of the Declaration of Helsinki. Written informed consent
was obtained from all participants.
Subjects and Phenotypes
Our study comprised two discovery cohorts, the New England
Sibling Cohort (NESC) that has 1,011 individuals including 500
sibpairs and an unrelated cohort from central Greece with 344
unrelated subjects (GREEK). Replication of findings from this
sample was sought in a cohort of 1,528 unrelated subjects from the
Nurses’ Health Study and Health Professionals Follow-up Study
(NHS-HPFS). Details of recruitment, diagnostic criteria and
subject classification for the NESC are described elsewhere.[28,39]
In brief, at least one individual from each family had the
neovascular (wet) form of AMD in at least one eye after excluding
patients with a retinal pigment epithelium detachment, myopia,
ocular histoplasmosis syndrome, angioid streaks, choroidal rup-
ture, any hereditary retinal diseases other than AMD, and
previous laser treatment for retinal conditions other than AMD.
A total of 352 wet AMD probands, 106 early/intermediate dry
probands (Age Related Eye Disease Study [AREDS] category 2
and 3), and 198 normal siblings from 284 families comprising 352
wet AMD sibpairs and 76 early/intermediate dry sibpairs were
available for this study. All but 87 of the sibpairs were discordant
for AMD. The GREEK cohort was enrolled at the University
Hospital of Larissa outpatient medical clinics in central Greece.
The diagnosis of AMD in this cohort was confirmed by optical
coherence tomography and Fluorescein angiography.[28,39] A
total of 139 wet AMD cases, 68 early and intermediate dry AMD
cases, and 213 controls with normal macula were available after
excluding patients with geographic atrophy. The NHS-HPFS
comprised 1,070 controls, 164 wet AMD cases, and 293 dry AMD
cases. We used two different definitions for affection status, wet
AMD and dry AMD, after excluding patients with geographic
atrophy[33].
Genotyping
Initially, genotyping was performed with tagging single
nucleotide polymorphisms (SNPs) from the ROBO1 gene. To
assess variation within this gene, tag SNPs were chosen to span the
ROBO1 gene using data from the HapMap (http://www.hapmap.
org/) after applying for the following criteria: 1) minor allele
frequency was greater than 10%, 2) linkage disequilibrium (LD; r
2)
was at least 0.8, and 3) tagged for at least 6 other SNPs. These
SNPs were genotyped using a combination of Sequenom and
TaqMan. For the SNPs genotyped via Sequenom, multiplex PCR
assays were designed using Sequenom SpectroDESIGNER
software (version 3.0.0.3) (Sequenom, San Diego, CA) by inputting
sequence containing the SNP site and 100 base pair (bp) of
flanking sequence on either side of the SNP. Briefly, 10 ng of
genomic DNA was amplified in a 5 uL reaction containing 1X
HotStar Taq PCR buffer (Qiagen, Valencia, CA), 1.625 mM
MgCl2, 500 uM each dNTP, 100 nM each PCR primer, 0.5 U
Figure 3. Results from gene expression studies in ROBO1. Absolute expression of ROBO1 in the RPE-Choroid is plotted on the Y-axis, and
values for the macula and extra macula are plotted for both normal eyes and eyes with all AMD subtypes.
doi:10.1371/journal.pone.0025775.g003
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15 minutes followed by 45 cycles of 94uC for 20 seconds, 56uC for
30 seconds, 72uC for 1 minute, followed by 3 minutes at 72uC.
Excess dNTPs were then removed from the reaction by incubation
with 0.3 U shrimp alkaline phosphatase (USB, Cleveland, OH) at
37uC for 40 minutes followed by 5 minutes at 85uC to deactivate
the enzyme. Single primer extension over the SNP was carried out
in a final concentration of between 0.625 uM and 1.5 uM for each
extension primer (depending on the mass of the probe), iPLEX
termination mix (Sequenom) and 1.35 U iPLEX enzyme
(Sequenom) and cycled using a two-step 200 short cycles program;
94uC for 30 seconds followed by 40 cycles of 94uC for 5 seconds, 5
cycles of 52uC for 5 seconds, and 80uC for 5 seconds, then 72uC
for 3 minutes. The reaction was then desalted by addition of 6 mg
cation exchange resin followed by mixing and centrifugation to
settle the contents of the tube. The extension product was then
spotted onto a 384 well SpectroCHIP before being flown in the
MALDI-TOF mass spectrometer. Data was collected, real time,
using SpectroTYPER Analyzer 3.3.0.15, SpectraAQUIRE 3.3.1.1
and SpectroCALLER 3.3.0.14 (Sequenom). Additionally, to
ensure data quality, genotypes for each subject was also checked
manually. For the SNPs genotyped via TaqMan, either TaqMan
Pre-Designed SNP Genotyping Assays or Custom TaqMan SNP
Genotyping Assays (Applied Biosystems) kits were ordered (for
listing of SNPs and probes, see Table S2). The 40X stock of the
probes were diluted to 16X with 0.5X tris-EDTA and stored at
220uC. The amplification reaction was carried out in a total
reaction volume of 16.25 mL containing 2.5 mL DNA (10ng),
1.25 mL of 16X probe, and 12.5 mL of TaqMan Genotyping
Master Mix. Sample DNA was amplified using the following
reaction: 1 min at 60uC, 10 min at 95uC, and 40 cycles of 15 sec.
at 92uC and 1 min at 60uC. The amplification reaction is carried
out on thermocyclers and then fluorescence is measured on the
ABI 7500 Real-Time PCR System by which the genotypes are
analyzed with the accompanying software, or, in some cases,
manually.
All genotyped SNPs met quality control thresholds of call rate of
at least 90% and being in Hardy-Weinberg equilibrium (HWE)
(P.0.01). LD among ROBO1 SNPs was evaluated using the
HapMap CEU reference population. At least one SNP from each
haplotype block, delineated on the basis of pairwise estimates of
LD (r
2) .0.5, was further analyzed under different genetic models
and in the interaction analyses. This SNP selection scheme both
sufficiently accounts for the potential contribution of ROBO1
individually and through interaction with RORA to AMD risk and
minimizes the penalty of multiple testing.
Sequencing
Based on the location of the significant SNPs found in the initial
screen of ROBO1, direct sequencing was also performed on the
promoter and exons 1, 2, and 3 in order to discover novel
variation. For these reactions, oligonucleotide primers were
selected using the Primer3 program http://primer3.sourceforge.
net/) to encompass the SNP and flanking intronic sequences. All
PCR assays were performed using genomic DNA fragments from
20 ng of leukocyte DNA in a solution of 10 PCR buffer containing
25 mM of MgCl2, 0.2 mM each of dATP, dTTP, dGTP, and
dCTP, and 0.5 U of Taq DNA polymerase (USB Corporation).
Five molar betaine was added to the reaction mix for rs2414687
(Sigma–Aldrich, St. Louis, MO). The temperatures used during
the polymerase chain reaction were as follows: 95uC for 5 min
followed by 35 cycles of 58uC for 30 s, 72uC for 30 s and 95uC for
30 s, with a final annealing at 58uC for 1.5 min and extension of
72uC for 5 min. For sequencing reactions, PCR products were
digested according to manufacturer’s protocol with ExoSAP-IT
(USB Corporation) then were subjected to a cycle sequencing
reaction using the Big Dye Terminator v 3.1 Cycle Sequencing kit
(Applied Biosystems, Foster City, CA) according to manufacturer’s
protocol. Products were purified with Performa DTR Ultra 96-
well plates (Edge Biosystems, Gaithersburg, MD) in order to
remove excess dye terminators. Samples were sequenced on an
ABI Prism 3100 DNA sequencer (Applied Biosystems). Electro-
pherograms generated from the ABI Prism 3100 were analyzed
using the Lasergene DNA and protein analysis software (DNAS-
TAR, Inc., Madison, WI). Electropherograms were read inde-
pendently by two evaluators without knowledge of the subject’s
disease status. All patients were sequenced in the forward direction
(5’–3’), unless variants or polymorphisms were identified, in which
case confirmation was obtained in some cases by sequencing in the
reverse direction.
Statistical Analysis
Linkage disequilibrium (LD) among the genotyped SNPs was
determined using Haploview (version 4.2; http://www.broad-
institute.org/scientific-community/science/programs/medical-and-
population-genetics/haploview/haploview). ROBO1 SNPs were
tested for association with wet and dry AMD classification groups
in the discovery cohorts using a logistic regression approach under
an additive model including age and sex as covariates. Generalized
Estimating Equations (GEE) were used in the analysis of the family
dataset to account for familial correlations[40] and a generalized
linear model approach was used for the unrelated cohorts. All
analyses were performed using the R package (R2.2.1; http://www.
r-project.org/). Haplotype analysis was performed using UNPHASED
(version 3.1.4; http://homepages.lshtm.ac.uk/frankdudbridge/software/
unphased/)[41,42] which can account for family- based data. Association
results obtained from individual datasets were combined by meta-analysis
using the inverse variance method implemented in the software package
METAL (http://www.sph.umich.edu/csg/abecasis/Metal/).[43] Effect
sizes were determined by summing the regression coefficients weighted by
the inverse variance of the coefficients. Significant findings from the
combined discovery cohorts were evaluated for association in the
replication sample. Results from the three cohorts were combined by
meta-analysis. SNPs with nominally significant P values (, 0.05) in the
combined sample (meta P) were further tested under dominant and
recessive models.
Four nominally significant SNPs (meta P,0.05) from the
ROBO1 gene were selected for interaction analysis. Association of
RORA SNPs for wet AMD was confirmed using haplotype analysis
using the UNPHASED program. One RORA SNP (rs8034864)
was selected from haplotype analysis results for tests of interaction
with ROBO1. Interaction of each of four ROBO1 SNPs with a
RORA SNP was assessed by comparing a baseline additive model,
which includes an independent term for each SNP, to the full
additive model which includes the SNP main effects plus an
interaction term. Significant findings in the discovery datasets were
tested for confirmation in the NHS-HPFS cohort. Using the
estimates from the meta-analysis, probabilities from a full logistic
model, Ph(X) =1/{1+exp[-(a+b1SNP1+ b2SNP2+ b3SNP1 xSNP2)]},
under the assumption of the same age and sex was calculated for each
genotypic categories for wet and dry AMD and plotted against
grouped genotypes from the two interacting SNPs.
Chromatin Immunoprecipitation and Quantitative (real
time) RT-PCR
Total RNA was isolated from P30.5 eyes (n=8) from B6 mice
using Trizol for quantitative real time—PCR (qRT-PCR). Sample
preparation, qRT-PCR reaction and analysis were performed as
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was performed on P30 retinal lysates from B6 mice as described
previously.[44] Briefly, immunoprecipitation was performed over-
night with 4ug of Rora antibody (goat, Santa Cruz Biotechnology) and
immunoglobulin (Ig) antibody (goat, R&D Systems). Quantitative
RT-PCR was performed using 4ul of Rora, 4ul of IgG, and 2ul of
input using real-time conditions described previously.[29] Tested
genes included the ‘‘locus control region’’ (response site) of Opn1mw
and the response site on Robo1. Opn1mw-LCR was used as a positive
control as previously published [29] and is located 3,896bp from the
start codon. An approximately 200 base pair region surrounding the
Robo 1 response element sequence region was amplified using
primers: Robo1F 3’ CATTTGGACCTTGTGTGTCT 5’, Robo1R:
3’ GTCTCTGCCACAATCTCACT 5’. To map this mouse
variation to the corresponding sequence in human, Ensembl genomic
alignments were used: for mouse, Robo1 ENSMUSG00000022883
and for human, ROBO1 ENSG00000169855 was used.
RPE-Choroid Expression Profile Assessment
Whole transcriptome expression profiles were obtained from
126 RPE-choroid and 118 retina punches (each 6mm in diameter)
obtained from the macular and extramacular regions of eyes from
66 human donors. These eyes were selected from a well-
characterized repository including 3,903 donors collected over a
20 year period at the University of Iowa and St. Louis University
by Dr. Hageman. Medical and ophthalmic histories, a family
questionnaire, blood, and sera, were obtained from the majority of
donors. Gross pathologic features, as well as the corresponding
fundus photographs and angiograms, when available, of all eyes in
this repository were read and classified by retinal specialists. Fundi
and/or posterior poles were graded using a slightly modified
version of two standardized classification systems, as published
previously.[45-49] The ages of the donors ranged from 9 to 101
years; approximately 50% had documented clinical histories of
AMD. RNA expression profiles were assessed using two-color,
44K Agilent Whole Genome in situ oligonucleotide microarray
analysis and a universal reference RNA experimental design. The
universal reference RNA consisted of a 1:1 pool of RPE-choroid
and retina RNA generated from donors with and without AMD.
After correcting for dye effects using LOWESS normalization, the
net intensity values were determined and expressed as a
percentage of the total array intensity. The ratios of the
experimental and reference RNA signals were calculated, and
then the normalized percent total of each experimental value was
calculated by multiplication using the geometric mean of all
determinations of each probe’s reference RNA value. For those
probes with replicates in the array, the average values were
determined. Inter-array differences were further corrected by
quantile normalization and probes that did not have net intensities
values greater than six times the standard deviation of the
background in at least 5% of the samples were omitted. This
resulted in a final data set comprised of 28,127 unique probes.
Expression of the ROBO1 and RORA genes was examined.
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